Liver X receptor agonist inhibits proliferation of ovarian carcinoma cells stimulated by oxidized low density lipoprotein

Gynecologic Oncology

Volumn 116, Issue 1, 2010, Pages 109-116

  Scoles, Daniel R ^a,b   Xu, Xuan ^a   Wang, Haimei ^a   Tran, Hang ^a   Taylor Harding, Barbie ^b   Li, Andrew ^a,b   Karlan, Beth Y ^a,b  

^a BURNS AND ALLEN RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chemoresistance; Fluvastatin; LXR agonist; Ovarian cancer; Oxidized LDL; Statin; TO901317

Indexed keywords

ABC TRANSPORTER A1; CARDIOTROPHIN 1; CD36 ANTIGEN; CISPLATIN; CYTOKINE; FLUINDOSTATIN; LIVER X RECEPTOR; LOW DENSITY LIPOPROTEIN; N (2,2,2 TRIFLUOROETHYL) N [4 (2,2,2 TRIFLUORO 1 HYDROXY 1 TRIFLUOROMETHYLETHYL)PHENYL]BENZENESULFONAMIDE; OXIDIZED LOW DENSITY LIPOPROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER SURVIVAL; CELL PROLIFERATION; CHEMOSENSITIVITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; IC 50; MITOGENESIS; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

CELL GROWTH PROCESSES; CELL LINE, TUMOR; DRUG INTERACTIONS; FATTY ACIDS, MONOUNSATURATED; FEMALE; HUMANS; HYDROCARBONS, FLUORINATED; INDOLES; LIGANDS; LIPOPROTEINS, LDL; ORPHAN NUCLEAR RECEPTORS; OVARIAN NEOPLASMS; SULFONAMIDES;

EID: 70749157037     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.09.034     Document Type: Article

References (33)

1. Tanne J.H. Meta-analysis says low LDL cholesterol may be associated with greater risk of cancer. BMJ 335 (2007) 177
2. Chang A.K., Barrett-Connor E., and Edelstein S. Low plasma cholesterol predicts an increased risk of lung cancer in elderly women. Prev. Med. 24 (1995) 557-562
3. Fiorenza A.M., Branchi A., and Sommariva D. Serum lipoprotein profile in patients with cancer. A comparison with non-cancer subjects. Int. J. Clin. Lab. Res. 30 (2000) 141-145
4. Genkinger J.M., Hunter D.J., Spiegelman D., et al. A pooled analysis of 12 cohort studies of dietary fat, cholesterol and egg intake and ovarian cancer. Cancer Causes Control 17 (2006) 273-285
5. Delimaris I., Faviou E., Antonakos G., Stathopoulou E., Zachari A., and Dionyssiou-Asteriou A. Oxidized LDL, serum oxidizability and serum lipid levels in patients with breast or ovarian cancer. Clin. Biochem. 40 (2007) 1129-1134
6. Elmore R.G., Ioffe Y., Scoles D.R., Karlan B.Y., and Li A.J. Impact of statin therapy on survival in epithelial ovarian cancer. Gynecol. Oncol. 111 (2008) 102-105
7. Jamroz-Wisniewska A., Wojcicka G., Horoszewicz K., and Beltowski J. Liver X receptors (LXRs). Part II: non-lipid effects, role in pathology, and therapeutic implications. Postepy. Hig. Med. Dosw. (Online) 61 (2007) 760-785
8. Hogue J.C., Lamarche B., Tremblay A.J., Bergeron J., Gagne C., and Couture P. Differential effect of atorvastatin and fenofibrate on plasma oxidized low-density lipoprotein, inflammation markers, and cell adhesion molecules in patients with type 2 diabetes mellitus. Metabolism 57 (2008) 380-386
9. Inami S., Okamatsu K., Takano M., et al. Effects of statins on circulating oxidized low-density lipoprotein in patients with hypercholesterolemia. Jpn. Heart J. 45 (2004) 969-975
10. Resch U., Tatzber F., Budinsky A., and Sinzinger H. Reduction of oxidative stress and modulation of autoantibodies against modified low-density lipoprotein after rosuvastatin therapy. Br. J. Clin. Pharmacol. 61 (2006) 262-274
11. van Tits L.J., van Himbergen T.M., Lemmers H.L., de Graaf J., and Stalenhoef A.F. Proportion of oxidized LDL relative to plasma apolipoprotein B does not change during statin therapy in patients with heterozygous familial hypercholesterolemia. Atherosclerosis 185 (2006) 307-312
12. Hofnagel O., Luechtenborg B., Weissen-Plenz G., and Robenek H. Statins and foam cell formation: impact on LDL oxidation and uptake of oxidized lipoproteins via scavenger receptors. Biochim. Biophys. Acta 1771 (2007) 1117-1124
13. Joseph S.B., Castrillo A., Laffitte B.A., Mangelsdorf D.J., and Tontonoz P. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat. Med. 9 (2003) 213-219
14. Freeman M.W., and Moore K.J. eLiXiRs for restraining inflammation. Nat. Med. 9 (2003) 168-169
15. Joseph S.B., McKilligin E., Pei L., et al. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 7604-7609
16. Blaschke F., Leppanen O., Takata Y., et al. Liver X receptor agonists suppress vascular smooth muscle cell proliferation and inhibit neointima formation in balloon-injured rat carotid arteries. Circ. Res. 95 (2004) e110-23
17. Zettler M.E., Prociuk M.A., Austria J.A., Massaeli H., Zhong G., and Pierce G.N. OxLDL stimulates cell proliferation through a general induction of cell cycle proteins. Am. J. Physiol. Heart Circ. Physiol. 284 (2003) H644-H653
18. Scoles D.R., Pavelka J., Cass I., et al. Characterization of CSOC 882, a novel immortalized ovarian cancer cell line expressing EGFR, HER2, and activated AKT. Gynecol. Oncol. 104 (2007) 120-128
19. Rasband WS. ImageJ, National Institutes of Health, Bethesda, Maryland, USA. In: http://rsb.info.nih.gov/ij/; 2004.
20. Farwell W.R., Scranton R.E., Lawler E.V., et al. The association between statins and cancer incidence in a veterans population. J. Natl. Cancer Inst. 100 (2008) 134-139
21. Czech C., Burns M.P., Vardanian L., et al. Cholesterol independent effect of LXR agonist TO-901317 on gamma-secretase. J. Neurochem. 101 (2007) 929-936
22. Chuu C.P., Kokontis J.M., Hiipakka R.A., and Liao S. Modulation of liver X receptor signaling as novel therapy for prostate cancer. J. Biomed. Sci. 14 (2007) 543-553
23. Chuu C.P., Hiipakka R.A., Kokontis J.M., Fukuchi J., Chen R.Y., and Liao S. Inhibition of tumor growth and progression of LNCaP prostate cancer cells in athymic mice by androgen and liver X receptor agonist. Cancer Res. 66 (2006) 6482-6486
24. Chuu C.P., Chen R.Y., Hiipakka R.A., et al. The liver X receptor agonist T0901317 acts as androgen receptor antagonist in human prostate cancer cells. Biochem. Biophys. Res. Commun. 357 (2007) 341-346
25. Gauthaman K., Richards M., Wong J., and Bongso A. Comparative evaluation of the effects of statins on human stem and cancer cells in vitro. Reprod. Biomed. Online 15 (2007) 566-581
26. Sassano A., and Platanias L.C. Statins in tumor suppression. Cancer Lett. 260 (2008) 11-19
27. Campbell M.J., Esserman L.J., Zhou Y., et al. Breast cancer growth prevention by statins. Cancer Res. 66 (2006) 8707-8714
28. Pennica D., Wood W.I., and Chien K.R. Cardiotrophin-1: a multifunctional cytokine that signals via LIF receptor-gp 130 dependent pathways. Cytokine Growth Factor Rev. 7 (1996) 81-91
29. Yang Z.F., Lau C.K., Ngai P., et al. Cardiotrophin-1 enhances regeneration of cirrhotic liver remnant after hepatectomy through promotion of angiogenesis and cell proliferation. Liver Int. 28 (2008) 622-631
30. Fritzenwanger M., Meusel K., Foerster M., Kuethe F., Krack A., and Figulla H.R. Cardiotrophin-1 induces interleukin-6 synthesis in human monocytes. Cytokine 38 (2007) 137-144
31. Zvonic S., Hogan J.C., Arbour-Reily P., Mynatt R.L., and Stephens J.M. Effects of cardiotrophin on adipocytes. J. Biol. Chem. 279 (2004) 47572-47579
32. Hirano T. Interleukin 6 and its receptor: ten years later. Int. Rev. Immunol. 16 (1998) 249-284
33. Natal C., Fortuño M.A., Restituto P., et al. Cardiotrophin-1 is expressed in adipose tissue and upregulated in the metabolic syndrome. Am J Physiol Endocrinol Metab 294 (2008) E52-E60